UV absorption at 595 nm, increased by the metabolic action of live MT-2 cells on an assay reagent, 13 was monitored as a surrogate for cell viability in the presence of increasing concentrations of ARM-H alone (white circles) or ARM-H plus live HIV-1 virus (black circles).
We next investigated the ability of ARM-H to recruit antibodies to gp120 both in vitro and in tissue culture. To this end, initial ELISA experiments ( Figure S2 ) demonstrated a concentrationdependent increase in anti-DNP antibody binding to the ARM-H-gp120 complex but not to gp120 alone. Thus, ARM-H is capable of templating a ternary complex that also includes gp120 and anti-DNP antibody.
To demonstrate that this ternary association could form in a complex cellular milieu, we evaluated the ability of ARM-H to recruit Alexa Fluor 488-labeled anti-DNP antibodies to HIVEnv-expressing Chinese hamster ovary cells (CHO-gp120 cells) 14 by immunofluorescence microscopy. As depicted in Figure 3 , a strong fluorescence signal was observed when CHO-gp120 cells were incubated with ARM-H and labeled anti-DNP antibodies (Figure 3a,b) . 15 This fluorescence was absent from both CHOgp120 cells not treated with ARM-H (Figure 3c,d ) and CHO cells not coding for HIV-enV gene expression (CHO-WT cells, Figure 3e ,f). Furthermore, the intense fluorescence observed in Figure 3b was considerably diminished in the presence of the competing ligands soluble CD4 (sCD4, Figure 3g ,h), BMS-378806 (Figure 3i ,j), and a DNP-containing alkyne that lacks the gp120-binding motif (2, Figure 3k ,l). Taken together, these results provide strong evidence that ARM-H is capable of recruiting anti-DNP antibodies to cells expressing the Env glycoprotein in a fashion that depends upon its simultaneous binding to both gp120 and anti-DNP antibodies.
Finally, we explored whether the ternary complex formed from anti-DNP antibody, ARM-H, and a live Env-expressing cell could activate complement proteins and mediate cellular death. Complement proteins are known to lyse cells by forming pores in lipid membranes and have been shown to play a critical role in inactivating HIV in humans. 16, 17 Thus, rabbit complement proteins were added to CHO-gp120 cells in the presence of ARM-H and a fixed concentration anti-DNP antibodies ( Figure  4 ). Substantial cell killing that exhibited a significant dependence on the ARM-H concentration (data in red) was observed. 18, 19 Notably, in the absence of anti-DNP antibody and complementpreserved serum (data in green), in cells lacking the Env glycoprotein (CHO-WT, data in black), or in the presence of 3, which lacks the DNP group (data in blue), no cell death was observed, suggesting that termolecular complex formation is necessary for complement-dependent cytotoxicity (CDC) and that ARM-H itself is not toxic to cells. Positive control experiments in which cells were directly labeled with 2,4-dinitrobenzenesulfonic acid ( Figure S4 ) were found to yield levels of CDC comparable to those observed for ARM-H, providing a benchmark for the assay results depicted in Figure 4 . Thus, ARM-H is capable of recruiting a functional complement-dependent cytotoxic response against Env-expressing cells.
Thus, we have shown that the bifunctional small molecule ARM-H can both recruit anti-DNP antibodies to gp120-expressing cells and inhibit the gp120-CD4 interaction. Data supporting these conclusions include the following: (1) ARM-H binds to gp120 competitively with CD4 and decreases viral infectivity in an MT-2 cell assay. (2) The small molecule can guide the formation of a ternary complex that includes anti-DNP antibodies and Envexpressing cells. (3) Antibodies present in this ternary complex can promote the complement-mediated killing of Env-expressing cells. Critically, no nonspecific cytotoxicity was observed in either MT-2 or CHO cell lines in response to ARM-H. Also, ARM-H-mediated inhibition of HIV entry and CDC activity were both operative at concentrations ranging from 6 to 30 µM, confirming that ARM-H could function simultaneously through dual mechanisms under therapeutic conditions. While a few methods for recruiting naturally occurring antibodies to cancer cells, 21-27 bacteria, 28-31 and viruses, [32] [33] [34] have appeared in the literature, this area remains underexplored. In the HIV realm, all such approaches have relied upon proteinor peptide-based antibody targeting constructs. For example, Shokat and Schultz 32 first demonstrated that anti-DNP antibodies could be redirected to immobilized protein targets (gp120 and streptavidin) as a therapeutic strategy toward HIV. More recent work in this vein has employed peptide-R-Gal conjugates to target human anti-Gal antibodies to HIV-infected cells.
33,34 These peptide conjugates were shown to be effective in killing Envexpressing cells but were also found to exhibit some nonspecific cytotoxicity.
28 ARM-H is unique in that it represents a smallmolecule-based anti-HIV strategy and targets the virus lifecycle through mutually reinforcing molecular mechanisms: it both prevents virus entry and targets Env-expressing cells for immune recognition and clearance. In general, small molecules have certain advantages over proteins from a therapeutic standpoint Env-expressing CHO cells (+gp120) or control cells lacking Env (-gp120) were treated with ARM-H (4) or control compound (3) at the indicated concentrations in the presence (+Ab) or absence (-Ab) of 10% complement-preserved rabbit serum and rat anti-DNP IgG (50 µg/mL). Values on the vertical axis correspond to % cell death (vs background). Each data point depicted represents the mean ( standard deviation of triplicate data from a representative experiment. The depicted trends were reproduced on at least three separate occasions. because of their low propensity for immunogenicity, high metabolic stability, ready large-scale production, and relatively low cost. Small-molecule antibody-recruiting therapeutics such as ARM-H would have additional benefits over available  treatment approaches to HIV. For example, directing HIVinfected cells and virus particles to Fcγ receptors on antigenpresenting cells could enhance the presentation of viral antigens  on MHC proteins and contribute to long-lasting anti-HIV  immunity. 26,35 Furthermore, because anti-DNP antibodies are already present in the human bloodstream, no pre-vaccination would be necessary for ARM-H activity. Also, the binding of bifunctional small-molecule targeting agents to antibodies should prolong their plasma half-life, thus increasing their effectiveness. 27 Elucidation of the molecular details governing the interactions among ARM-H, gp120, and anti-DNP antibodies will assist in optimization efforts as well as in the evaluation of this strategy in more complex biological models for HIV infection. These and other investigations are currently ongoing in our laboratories. University). Unless otherwise noted, all micro-plate based assays were quantitated using a BioTek Synergy 3
Microplate reader and data was fitted and graphed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego California USA, www.graphpad.com) or KaleidaGraph (Synergy Software). ELISA and CDC experiments were performed in triplicate and repeated at least three times unless otherwise noted.
Immunofluorescence (IF) experiments were performed in duplicate and repeated at least two times.
Supplementary Scheme 1. Synthesis of Alkyne-PEG-DNP (2)
1-azido-3,6,9,12-tetraoxapentadec-14-yne (6) 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanol 1 (7.55 g, 34 mmol, 1.0 equiv., 5) was dissolved in DMF (150mL), and sodium hydride (989 mg, 40.8 mmol, 1.2 equiv.) was added, followed by propargyl bromide (80% in PhMe, 7.4 mL, 68 mmol, 2.0 equiv.). The reaction ran for 3 h at rt, at which time it was found complete by thin layer chromatography, concentrated on a rotary evaporator, and chromatographed on silica gel (30% EtOAc in hexanes) to yield 6 as a clear oil (7.55 g, 86% yield 
N-(2,4-dinitrophenyl)-3,6,9,12-tetraoxapentadec-14-yn-1-amine (2)
To a solution of 3,6,9,12-tetraoxapentadec-14-yn-1-amine 7 (1.0 g, 4.3 mmol, 1 equiv.) dissolved in EtOH (18mL), was added triethylamine (1.68mL, 8.6mmol, 2 equiv.) and 1-chloro-2,4-dinitrobenzene (876 mg, 4.3 mmol, 1 equiv.) via syringe. The reaction flask was then fitted with a reflux condenser and the reaction was heated to reflux for 2 h, cooled, and concentrated to provide a crude yellow oil. The crude mixture was re-dissolved in H 2 O (25 mL) and extracted with CH 2 Cl 2 (5 x 10 mL). The organic layers were dried over Na 2 SO 4 and concentrated to a yellow oil that was further purified by flash chromatography (CombiFlash Automated Chromatographer, 25g column, dryloaded with 25g pre-packed dry loading column; gradient elution ranging from 10% EtOAc:Hexanes to 50%
EtOAc:Hexanes was performed over 30 column volumes, followed by an EtOAc flush) to yield 2 as a yellow solid ( 
4-Benzoyl-2-(R)-methyl-1-[(4-nitro-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-piperazine (8)
This compound was synthesized as previously described 2 . All synthetic intermediates as well as the final product analytical data were in agreement with that reported.
Azide (3)
To a stirred mixture of 255 mg NaH (95%, 9.88 mmol, 7.2 equiv, Aldrich), anhydrous dimethoxyethane (21 mL) was added followed by hexaethylene azido glycol 3 S5 dimethoxyethane (7.5 mL) via cannula at room temperature. The resulting copper-colored mixture was heated to 45 o C and monitored by TLC (9:1 CH 2 Cl 2 / CH 3 OH). After approximately 2 hrs, the mixture (now brown in color) was allowed to cool to room temperature, a saturated aqueous solution of NH 4 Cl (15 mL) was slowly added, and the organic layer was extracted with CH 2 Cl 2 (5 x 80 mL). The organic phases were combined, dried over anhydrous MgSO 4 , filtered, and all solvents were evaporated under reduced pressure. The resulting crude brown residue, containing compound 9, was purified chromatographically on silica (0% to 20% CH 3 OH in CH 2 Cl 2 ) to remove unreacted azido alcohol, and provided a yellow oil (650 mg), which was then dissolved in 40 mL EtOAc. To this solution was added 1.10 mL PCl 3 (6.92mmol, 10 equiv), resulting in a heterogeneous orange mixture, and allowed to stir at r.t. After 2 hrs, the reaction was cooled to 0 o C, and quenched by the careful addition of saturated aqueous NaHCO 3 until pH of 6 was reached. The mixture was extracted with EtOAc (5 x 50 mL), the combined organic layers were dried over anhydrous 
ARM-H (4)
To a solution of 2 (45.0 mg, 0.066 mmol) dissolved in t-BuOH (1.7 mL) and H 2 O (1.6 mL) was added 
MT-2 Cell Assay (Figure 2B and Supplementary Figure 1)
Antiviral activity and cellular toxicity were determined using the MTT colorimetric method 4, 5 . 
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goat anti-mouse antibody (1:2500; Biolegend; San Diego, CA). Bound antibody was detected with the chromogenic HRP substrate 3,3,5,5-tetramethylbenzidine (TMB, Pierce Protein Research Products), and absorbance was read at 450 nm. The means (±SD) of these triplicate samples were then plotted versus inhibitor concentration, and a nonlinear fit curve was generated using GraphPad Prism. The 50% inhibitory concentration (IC 50 ) was defined as the concentration of inhibitor to reduce the maximal amount of bound CD4 to gp120 by 50%. Figure 2) A. Varying ARM-H Concentration (Supplementary Figure 2A) Nunc-Immuno 96-well plates were coated with soluble gp120 and blocked as described above. After washing with PBS (Aldrich), the indicated concentrations of ARM-H (4) were added, and assay plates were incubated for 1 hr at RT. After washing (3x100 µL) the plate with Buffer D (50 mM Tris HCl, 100 mM NaCl, 23 mM HEPES, 1 mM Nunc-Immuno 96-well plates were coated with soluble gp120 and blocked as described above. After the PBS (Aldrich) wash, 25 µΜ of ARM-H (4) was added, and assay plates were allow to incubate for 1 hr at RT. After washing the plate with Buffer D (3x100 µL), wells were incubated with indicated concentrations of rat monoclonal anti-dinitrophenyl (anti-DNP) IgG antibodies (Zymed; Carlsbad, CA) in Buffer E at room temperature for 1 hr.
Anti-DNP IgG Recruiting ELISA's (Supplementary
Plates were then washed and incubated with HRP-conjugated goat anti-rat antibody. Bound antibody was detected Figure 2) , we utilized an ELISA buffer system that was compatible with tissue culture (i.e., one that lacks detergent) in order to model the conditions employed in subsequent CDC assays. Thus we would not expect an exact correlation between the competition ELISA IC 50 and the antibody recruiting ELISA EC 50 values. In addition, we recognize that the antibody/ARM-H/gp120 complex should exhibit auto-inhibitory behaviors consistent with ternary complex formation under certain circumstances, however, data collected in the antibody recruiting ELISA (Supp. Fig. 2) would not be expected to do so because a series of washes were performed prior to addition of anti-DNP antibody, thus removing unbound ARM-H, and preventing auto-inhibition by antibody/ARM-H complexes.
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CHO Cell Culture
Wild-type HIV-1 env expressing CHO-WT (described as 'CHO-gp120' in the text) cells were obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: CHO-WT from Dr. Carol Weiss and Dr. Judith White. Cells were grown on glutamine-deficient minimal essential medium containing 400 µM methionine sulfoximine ("GMEM-S selection media"; MSX, Sigma) as described by associated NIH protocol 12 .
CHO-K1 cells (described as "CHO-WT" in the text; ATCC) were grown in ATCC-formulated F-12K medium supplemented with 10% FBS (Gibco). Cells were detached from cell culture flasks with 2.5mM EDTA/0.5mM EGTA in DPBS (Gibco) for passage. *Note: As described in the associated NIH culture protocol, a drop in envelope expression in CHO-WT cells was observed upon several passages and it is recommended to maintain low passage stocks of cells in liquid nitrogen.
Immunofluorescence Microcopy (Figure 3) . Complement mediated cell death and cytotoxicity was calculated as: [1-((sample-max killing)/(untreated-max killing))] X 100 and plotted using GraphPad Prism. Raw data was subjected to Dixon Q-test analysis at the 90% confidence interval and statistical outliers were removed accordingly.
13,14
*Note: When performing above CDC analyses, authors observed consistent complement-dependent cytotoxicity results over several CHO-gp120 cell passages. However, as reported in the NIH culture protocol, we observed a decrease in envelope protein expression over many passages, as well as a consequent reduction in ARM-H (4)-mediated CDC. In addition, at higher concentrations of both ARM-H and azide (3) (>50µM), authors observed enhanced cell viability (decreased cell death) in both CHO-gp120 and CHO-WT cells, as shown in Supplementary   Figure 3 . Importantly, this effect was only observed at concentrations greater than ~50 µM, which is outside the concentration range reported in Figure 3 . Furthermore, since these effects lead to an enhancement in viability, they would tend to underestimate the effect of ARM-H mediated antibody-dependent cytotoxicity.
Nevertheless, we studied this phenomenon in more detail, and based upon follow up experiments, this enhancement in viability appears to be independent of the presence of antibody/complement and gp120. It is also not due to a Figure 3A) . Figure 4) A series of anti-gp120 antibodies were screened and subjected to the CDC assay conditions described above;
however, none of these were capable of mediating CDC under our conditions. These results are consistent with literature reports; to our knowledge, no available monoclonal or polyclonal anti-gp120 antibodies is capable of 15 Given that none of these were effective in CDC assays, our results underscore the potential utility of these reported small molecule conjugates All gp120 antibodies were tested at concentrations up to 50 µg/mL (ImmunoDiagnostics #3501 was tested up to 25 µg/mL) and were performed once in triplicate. CHO-WT cells were detached and re-suspended at a density of 9.00 X 10 5 cells/mL in Buffer E as described above. Subsequently, the cell suspension was added to prepared dilutions of anti-gp120 antibody in Buffer E. Resulting mixtures were plated in triplicate (50 µL 
